Drugs in Dev. Endocrinology
Undisclosed
France 
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine,Lixisenatide
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Soliqua® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin
Details : Participants were randomized to switch from their prior insulin to either Soliqua once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin or SGLT-2i treatment was maintained through the study period.
Product Name : Soliqua
Product Type : Peptide
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Insulin Glargine,Lixisenatide
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will focus on the integration of Novo Nordisk's new generation of connected pens, NovoPen® 6 and NovoPen Echo® Plus with DBL-4pen™. Diabeloop is planning a study for Type 2 diabetes to evaluate the efficacy and clinical benefits of ...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
